ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

as well so absolutely I think you should be thinking about two main factors you know new patient starts and active patients because it's going to be the active patients that we believe that we can continue to grow over time that are really going to be meaningful for the ongoing revenue uptick for this brand into the long term Liz, do you want to touch on our positioning versus the new Celina product? Sure. I'll start out with the fact that, I mean, we're delighted for the PWS community that there is now a first therapy available for them. That said, I think we see this as an area of significant high unmet need and complex patients who are dealing with a number of different challenges. It's the kind of space where we think that it's likely that there is going to be absolutely room for multiple agents that are used with different MOAs, with different benefit-risk profiles that physicians can use according to the patient that's in front of them. I don't know if there's anything you want to add here, Tom? Well, the only thing I would add is we know that the Prada Willy population, you know, they have very complex and distinct needs, and we actually believe that there's going to be an opportunity for more than one product to play here, and I think with therapeutic areas like this, the notion of combination therapy could also be something that plays out into the future as well. So a pretty substantial patient population here in the US, plenty of opportunity for more than one player to play, and we will be ready to launch should the data be positive. Yeah, and we do spend a lot of time, of course, talking to caregivers, advocacy organizations, and we hear pretty robustly that, again, they are delighted that there is something available for their family members now. And they...